Pathophysiology of Celiac Disease

Gastrointestinal Endoscopy Clinics of North America

Volumn 22, Issue 4, 2012, Pages 639-660

  Kupfer, Sonia S ^a,b   Jabri, Bana ^a,b  

^a University of Chicago Medicine   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Adaptive and innate immunity; Celiac disease; Deamidation; Gluten; HLA DQ2 and HLA DQ8; Intestinal microbiome; Single nucleotide polymorphisms

Indexed keywords

GLUTEN; HLA DQ2 ANTIGEN; HLA DQ8 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; PEPTIDE FRAGMENT;

ADAPTIVE IMMUNITY; ALLELE; ANTIGEN PRESENTING CELL; BACTEROIDES; BIFIDOBACTERIUM; CD4+ T LYMPHOCYTE; CELIAC DISEASE; CLOSTRIDIUM; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUTEN FREE DIET; HUMAN; IMMUNE DYSREGULATION; INNATE IMMUNITY; INTESTINE LYMPHATIC TISSUE; LACTOBACILLUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROFLORA; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; STAPHYLOCOCCUS;

CELIAC DISEASE; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GLUTENS; HLA-DQ ANTIGENS; HUMANS; TIME FACTORS;

EID: 84867670979     PISSN: 10525157     EISSN: 15581950     Source Type: Journal    
DOI: 10.1016/j.giec.2012.07.003     Document Type: Review

References (143)

1. Troncone R., Jabri B. Coeliac disease and gluten sensitivity. J Intern Med 2011, 269:582-590.
2. Losowsky M.S. A history of coeliac disease. Dig Dis 2008, 26:112-120.
3. Dicke W.K., Weijers H.A., van de Kamer J.H. Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr 1953, 42:34-42.
4. *0201. Tissue Antigens 1993, 41:173-177.
5. van Belzen M.J., Koeleman B.P., Crusius J.B., et al. Defining the contribution of the HLA region to cis DQ2-positive coeliac disease patients. Genes Immun 2004, 5:215-220.
6. Mearin M.L., Biemond I., Pena A.S., et al. HLA-DR phenotypes in Spanish coeliac children: their contribution to the understanding of the genetics of the disease. Gut 1983, 24:532-537.
7. Janeway C.A., Travers P. Immunobiology: the immune system in health and disease 1997, vol. 1. Current Biology Ltd./Garland Publishing Inc, London and New York, p. 24-1, 25. 3rd edition.
8. Marsh S.G., for the WHO Nomenclature Committee for Factors of the HLA System Nomenclature for factors of the HLA system, update January 2012. Tissue Antigens 2012, 79:393-397.
9. Megiorni F., Mora B., Bonamico M., et al. HLA-DQ and risk gradient for celiac disease. Hum Immunol 2009, 70:55-59.
10. Vader W., Stepniak D., Kooy Y., et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A 2003, 100:12390-12395.
11. Zubillaga P., Vidales M.C., Zubillaga I., et al. HLA-DQA1 and HLA-DQB1 genetic markers and clinical presentation in celiac disease. J Pediatr Gastroenterol Nutr 2002, 34:548-554.
12. *0201 allelic combination influences the clinical heterogeneity of celiac disease. Hum Immunol 1994, 40:138-142.
13. Al-Toma A., Goerres M.S., Meijer J.W., et al. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 2006, 4:315-319.
14. Fallang L.E., Bergseng E., Hotta K., et al. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat Immunol 2009, 10:1096-1101.
15. *02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003, 64:469-477.
16. The Allele Frequency Net Database. 2012. Available at: Accessed March 19, 2012. http://www.allelefrequencies.net.
17. Pietzak M.M., Schofield T.C., McGinniss M.J., et al. Stratifying risk for celiac disease in a large at-risk United States population by using HLA alleles. Clin Gastroenterol Hepatol 2009, 7:966-971.
18. Kim C.Y., Quarsten H., Bergseng E., et al. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci U S A 2004, 101:4175-4179.
19. Hovhannisyan Z., Weiss A., Martin A., et al. The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 2008, 456:534-538.
20. Molberg O., Kett K., Scott H., et al. Gliadin specific, HLA DQ2-restricted T cells are commonly found in small intestinal biopsies from coeliac disease patients, but not from controls. Scand J Immunol 1997, 46:103-109.
21. Molberg O., Mcadam S.N., Korner R., et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998, 4:713-717.
22. Arentz-Hansen H., Korner R., Molberg O., et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000, 191:603-612.
23. Arentz-Hansen H., McAdam S.N., Molberg O., et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002, 123:803-809.
24. Qiao S.W., Bergseng E., Molberg O., et al. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 2004, 173:1757-1762.
25. van de Wal Y., Kooy Y.M., van Veelen P.A., et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci U S A 1998, 95:10050-10054.
26. Shan L., Qiao S.W., Arentz-Hansen H., et al. Identification and analysis of multivalent proteolytically resistant peptides from gluten: implications for celiac sprue. J Proteome Res 2005, 4:1732-1741.
27. Henderson K.N., Tye-Din J.A., Reid H.H., et al. A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease. Immunity 2007, 27:23-34.
28. van Heel D.A., Franke L., Hunt K.A., et al. A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007, 39:827-829.
29. Hunt K.A., Zhernakova A., Turner G., et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 2008, 40:395-402.
30. Dubois P.C., Trynka G., Franke L., et al. Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010, 42:295-302.
31. Trynka G., Hunt K.A., Bockett N.A., et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011, 43:1193-1201.
32. Trynka G., Wijmenga C., van Heel D.A. A genetic perspective on coeliac disease. Trends Mol Med 2010, 16:537-550.
33. Abadie V., Sollid L.M., Barreiro L.B., et al. Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol 2011, 29:493-525.
34. van de Wal Y., Kooy Y.M., van Veelen P., et al. Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol 1999, 29:3133-3139.
35. Molberg O., Solheim Flaete N., Jensen T., et al. Intestinal T-cell responses to high-molecular-weight glutenins in celiac disease. Gastroenterology 2003, 125:337-344.
36. Dewar D.H., Amato M., Ellis H.J., et al. The toxicity of high molecular weight glutenin subunits of wheat to patients with coeliac disease. Eur J Gastroenterol Hepatol 2006, 18:483-491.
37. Vader L.W., Stepniak D.T., Bunnik E.M., et al. Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 2003, 125:1105-1113.
38. Arentz-Hansen H., Fleckenstein B., Molberg O., et al. The molecular basis for oat intolerance in patients with celiac disease. PLoS Med 2004, 1:e1.
39. Shan L., Molberg O., Parrot I., et al. Structural basis for gluten intolerance in celiac sprue. Science 2002, 297:2275-2279.
40. Hausch F., Shan L., Santiago N.A., et al. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002, 283:G996-G1003.
41. Stepniak D., Spaenij-Dekking L., Mitea C., et al. Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease. Am J Physiol Gastrointest Liver Physiol 2006, 291:G621-G629.
42. De Angelis M., Rizzello C.G., Fasano A., et al. VSL#3 probiotic preparation has the capacity to hydrolyze gliadin polypeptides responsible for celiac sprue. Biochim Biophys Acta 2006, 1762:80-93.
43. Heyman M., Abed J., Lebreton C., et al. Intestinal permeability in coeliac disease: insight into mechanisms and relevance to pathogenesis. Gut 2011, 61:1355-1364.
44. Wapenaar M.C., Monsuur A.J., van Bodegraven A.A., et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut 2008, 57:463-467.
45. Monsuur A.J., de Bakker P.I., Alizadeh B.Z., et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 2005, 37:1341-1344.
46. Fasano A., Baudry B., Pumplin D.W., et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci U S A 1991, 88:5242-5246.
47. Paterson B.M., Lammers K.M., Arrieta M.C., et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007, 26:757-766.
48. Tripathi A., Lammers K.M., Goldblum S., et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A 2009, 106:16799-16804.
49. Matysiak-Budnik T., Moura I.C., Arcos-Fajardo M., et al. Secretory IgA mediates retrotranscytosis of intact gliadin peptides via the transferrin receptor in celiac disease. J Exp Med 2008, 205:143-154.
50. Turnbaugh P.J., Ley R.E., Hamady M., et al. The human microbiome project. Nature 2007, 449:804-810.
51. Kau A.L., Ahern P.P., Griffin N.W., et al. Human nutrition, the gut microbiome and the immune system. Nature 2011, 474:327-336.
52. Petrosino J.F., Highlander S., Luna R.A., et al. Metagenomic pyrosequencing and microbial identification. Clin Chem 2009, 55:856-866.
53. Turnbaugh P.J., Hamady M., Yatsunenko T., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457:480-484.
54. Muegge B.D., Kuczynski J., Knights D., et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science 2011, 332:970-974.
55. Wikoff W.R., Anfora A.T., Liu J., et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A 2009, 106:3698-3703.
56. Murphy S.F., Kwon J.H., Boone D.L. Novel players in inflammatory bowel disease pathogenesis. Curr Gastroenterol Rep 2012, 14:146-152.
57. Forsberg G., Fahlgren A., Horstedt P., et al. Presence of bacteria and innate immunity of intestinal epithelium in childhood celiac disease. Am J Gastroenterol 2004, 99:894-904.
58. Tjellstrom B., Stenhammar L., Hogberg L., et al. Gut microflora associated characteristics in children with celiac disease. Am J Gastroenterol 2005, 100:2784-2788.
59. Di Cagno R., De Angelis M., De Pasquale I., et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol 2011, 11:219.
60. Tjellstrom B., Stenhammar L., Hogberg L., et al. Gut microflora associated characteristics in first-degree relatives of children with celiac disease. Scand J Gastroenterol 2007, 42:1204-1208.
61. Calvert V.S., Collantes R., Elariny H., et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007, 46:166-172.
62. Collado M.C., Donat E., Ribes-Koninckx C., et al. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol 2009, 62:264-269.
63. Sanz Y., Sanchez E., Marzotto M., et al. Differences in faecal bacterial communities in coeliac and healthy children as detected by PCR and denaturing gradient gel electrophoresis. FEMS Immunol Med Microbiol 2007, 51:562-568.
64. Schippa S., Iebba V., Barbato M., et al. A distinctive 'microbial signature' in celiac pediatric patients. BMC Microbiol 2010, 10:175.
65. Sanchez E., Donat E., Ribes-Koninckx C., et al. Intestinal Bacteroides species associated with coeliac disease. J Clin Pathol 2010, 63:1105-1111.
66. Nistal E., Caminero A., Herran A.R., et al. Differences of small intestinal bacteria populations in adults and children with/without celiac disease: effect of age, gluten diet, and disease. Inflamm Bowel Dis 2012, 18(4):649-656.
67. Kalliomaki M., Satokari R., Lahteenoja H., et al. Expression of microbiota, Toll-like receptors and their regulators in the small intestinal mucosa in celiac disease. J Pediatr Gastroenterol Nutr 2012, 54(6):727-732.
68. Sellitto M., Bai G., Serena G., et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants. PLoS One 2012, 7:e33387.
69. De Palma G., Nadal I., Collado M.C., et al. Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br J Nutr 2009, 102:1154-1160.
70. De Palma G., Cinova J., Stepankova R., et al. Pivotal advance: bifidobacteria and gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J Leukoc Biol 2010, 87:765-778.
71. D'Arienzo R., Maurano F., Lavermicocca P., et al. Modulation of the immune response by probiotic strains in a mouse model of gluten sensitivity. Cytokine 2009, 48:254-259.
72. Cinova J., De Palma G., Stepankova R., et al. Role of intestinal bacteria in gliadin-induced changes in intestinal mucosa: study in germ-free rats. PLoS One 2011, 6:e16169.
73. De Angelis M., Rizzello C.G., Scala E., et al. Probiotic preparation has the capacity to hydrolyze proteins responsible for wheat allergy. J Food Prot 2007, 70:135-144.
74. Ringel Y., Ringel-Kulka T. The rationale and clinical effectiveness of probiotics in irritable bowel syndrome. J Clin Gastroenterol 2011, 45(Suppl):S145-S148.
75. Sartor R.B. Key questions to guide a better understanding of host-commensal microbiota interactions in intestinal inflammation. Mucosal Immunol 2011, 4:127-132.
76. Kagnoff M.F., Austin R.K., Hubert J.J., et al. Possible role for a human adenovirus in the pathogenesis of celiac disease. J Exp Med 1984, 160:1544-1557.
77. Kagnoff M.F., Paterson Y.J., Kumar P.J., et al. Evidence for the role of a human intestinal adenovirus in the pathogenesis of coeliac disease. Gut 1987, 28:995-1001.
78. Kagnoff M.F. Celiac disease: adenovirus and alpha gliadin. Curr Top Microbiol Immunol 1989, 145:67-78.
79. Mahon J., Blair G.E., Wood G.M., et al. Is persistent adenovirus 12 infection involved in coeliac disease? A search for viral DNA using the polymerase chain reaction. Gut 1991, 32:1114-1116.
80. Lahdeaho M.L., Lehtinen M., Rissa H.R., et al. Antipeptide antibodies to adenovirus E1b protein indicate enhanced risk of celiac disease and dermatitis herpetiformis. Int Arch Allergy Immunol 1993, 101:272-276.
81. Vesy C.J., Greenson J.K., Papp A.C., et al. Evaluation of celiac disease biopsies for adenovirus 12 DNA using a multiplex polymerase chain reaction. Mod Pathol 1993, 6:61-64.
82. Ivarsson A., Hernell O., Nystrom L., et al. Children born in the summer have increased risk for coeliac disease. J Epidemiol Community Health 2003, 57:36-39.
83. Stene L.C., Honeyman M.C., Hoffenberg E.J., et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol 2006, 101:2333-2340.
84. Zanoni G., Navone R., Lunardi C., et al. In celiac disease, a subset of autoantibodies against transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med 2006, 3:e358.
85. Roberts S.E., Williams J.G., Meddings D., et al. Perinatal risk factors and coeliac disease in children and young adults: a record linkage study. Aliment Pharmacol Ther 2009, 29:222-231.
86. Decker E., Engelmann G., Findeisen A., et al. Cesarean delivery is associated with celiac disease but not inflammatory bowel disease in children. Pediatrics 2010, 125:e1433-e1440.
87. Marild K., Stephansson O., Montgomery S., et al. Pregnancy outcome and risk of celiac disease in offspring: a nationwide case-control study. Gastroenterology 2012, 142:39-45.e3.
88. Dominguez-Bello M.G., Costello E.K., Contreras M., et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010, 107:11971-11975.
89. Ivarsson A., Persson L.A., Nystrom L., et al. Epidemic of coeliac disease in Swedish children. Acta Paediatr 2000, 89:165-171.
90. Ivarsson A., Persson L.A., Nystrom L., et al. The Swedish coeliac disease epidemic with a prevailing twofold higher risk in girls compared to boys may reflect gender specific risk factors. Eur J Epidemiol 2003, 18:677-684.
91. Myleus A., Ivarsson A., Webb C., et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr 2009, 49:170-176.
92. Ivarsson A. The Swedish epidemic of coeliac disease explored using an epidemiological approach-some lessons to be learnt. Best Pract Res Clin Gastroenterol 2005, 19:425-440.
93. Norris J.M., Barriga K., Hoffenberg E.J., et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 2005, 293:2343-2351.
94. Akobeng A.K., Ramanan A.V., Buchan I., et al. Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch Dis Child 2006, 91:39-43.
95. Guandalini S. The influence of gluten: weaning recommendations for healthy children and children at risk for celiac disease. Nestle Nutr Workshop Ser Pediatr Program 2007, 60:139-151. [discussion: 151-5].
96. Liu S., Cerione R.A., Clardy J. Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc Natl Acad Sci U S A 2002, 99:2743-2747.
97. Pinkas D.M., Strop P., Brunger A.T., et al. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 2007, 5:e327.
98. Sollid L.M., Jabri B. Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders. Curr Opin Immunol 2011, 23:732-738.
99. Sollid L.M., Qiao S.W., Anderson R.P., et al. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 2012, 64(6):455-460.
100. Rostom A., Dube C., Cranney A., et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 2005, 128:S38-S46.
101. Sollid L.M., Jabri B. Is celiac disease an autoimmune disorder?. Curr Opin Immunol 2005, 17:595-600.
102. Lindfors K., Maki M., Kaukinen K. Transglutaminase 2-targeted autoantibodies in celiac disease: pathogenetic players in addition to diagnostic tools?. Autoimmun Rev 2010, 9:744-749.
103. Di Sabatino A., Vanoli A., Giuffrida P., et al. The function of tissue transglutaminase in celiac disease. Autoimmun Rev 2012, 11:746-753.
104. Di Niro R., Mesin L., Zheng N.Y., et al. High abundance of plasma cells secreting transglutaminase 2-specific IgA autoantibodies with limited somatic hypermutation in celiac disease intestinal lesions. Nat Med 2012, 18:441-445.
105. Caja S., Myrsky E., Korponay-Szabo I.R., et al. Inhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies. Scand J Gastroenterol 2010, 45:421-427.
106. Myrsky E., Kaukinen K., Syrjanen M., et al. Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin Exp Immunol 2008, 152:111-119.
107. Barone M.V., Caputo I., Ribecco M.T., et al. Humoral immune response to tissue transglutaminase is related to epithelial cell proliferation in celiac disease. Gastroenterology 2007, 132:1245-1253.
108. Esposito C., Paparo F., Caputo I., et al. Expression and enzymatic activity of small intestinal tissue transglutaminase in celiac disease. Am J Gastroenterol 2003, 98:1813-1820.
109. Dieterich W., Trapp D., Esslinger B., et al. Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity. Gut 2003, 52:1562-1566.
110. Kiraly R., Vecsei Z., Demenyi T., et al. Coeliac autoantibodies can enhance transamidating and inhibit GTPase activity of tissue transglutaminase: dependence on reaction environment and enzyme fitness. J Autoimmun 2006, 26:278-287.
111. Sardy M., Karpati S., Merkl B., et al. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002, 195:747-757.
112. du Pre M.F., Samsom J.N. Adaptive T-cell responses regulating oral tolerance to protein antigen. Allergy 2011, 66:478-490.
113. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007, 204:1757-1764.
114. Sun C.M., Hall J.A., Blank R.B., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007, 204:1775-1785.
115. DePaolo R.W., Abadie V., Tang F., et al. Co-adjuvant effects of retinoic acid and IL-15 induce inflammatory immunity to dietary antigens. Nature 2011, 471:220-224.
116. MacDonald T.T., Ferguson A. Hypersensitivity reactions in the small intestine. 2. Effects of allograft rejection on mucosal architecture and lymphoid cell infiltrate. Gut 1976, 17:81-91.
117. Ferguson A., MacDonald T.T., McClure J.P., et al. Cell-mediated immunity to gliadin within the small-intestinal mucosa in coeliac disease. Lancet 1975, 1:895-897.
118. *0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993, 178:187-196.
119. Lundin K.E., Gjertsen H.A., Scott H., et al. Function of DQ2 and DQ8 as HLA susceptibility molecules in celiac disease. Hum Immunol 1994, 41:24-27.
120. Nilsen E.M., Lundin K.E., Krajci P., et al. Gluten specific, HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 1995, 37:766-776.
121. Nilsen E.M., Jahnsen F.L., Lundin K.E., et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 1998, 115:551-563.
122. Salvati V.M., MacDonald T.T., Bajaj-Elliott M., et al. Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease. Gut 2002, 50:186-190.
123. Monteleone G., Pender S.L., Alstead E., et al. Role of interferon alpha in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 2001, 48:425-429.
124. Cammarota G., Cuoco L., Cianci R., et al. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 2000, 356:1494-1495.
125. George E.K., Mearin M.L., Bouquet J., et al. High frequency of celiac disease in Down syndrome. J Pediatr 1996, 128:555-557.
126. Gerdes A.M., Horder M., Bonnevie-Nielsen V. Increased IFN-alpha-induced sensitivity but reduced reactivity of 2',5'-oligoadenylate synthetase (2,5AS) in trisomy 21 blood lymphocytes. Clin Exp Immunol 1993, 93:93-96.
127. Jabri B., Sollid L.M. Mechanisms of disease: immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 2006, 3:516-525.
128. Cellier C., Delabesse E., Helmer C., et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000, 356:203-208.
129. Jabri B., Ebert E. Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue. Immunol Rev 2007, 215:202-214.
130. Hue S., Mention J.J., Monteiro R.C., et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004, 21:367-377.
131. Meresse B., Chen Z., Ciszewski C., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004, 21:357-366.
132. Meresse B., Curran S.A., Ciszewski C., et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med 2006, 203:1343-1355.
133. Bauer S., Groh V., Wu J., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285:727-729.
134. Braud V.M., Allan D.S., O'Callaghan C.A., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799.
135. Roberts A.I., Lee L., Schwarz E., et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001, 167:5527-5530.
136. Tang F., Chen Z., Ciszewski C., et al. Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15. J Exp Med 2009, 206:707-719.
137. Kasaian M.T., Whitters M.J., Carter L.L., et al. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 2002, 16:559-569.
138. Perera L., Shao L., Patel A., et al. Expression of nonclassical class I molecules by intestinal epithelial cells. Inflamm Bowel Dis 2007, 13:298-307.
139. Rubio-Tapia A., Murray J.A. Classification and management of refractory coeliac disease. Gut 2010, 59:547-557.
140. Rubio-Tapia A., Kelly D.G., Lahr B.D., et al. Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 2009, 136:99-107. [quiz: 352-3].
141. Malamut G., El Machhour R., Montcuquet N., et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest 2010, 120:2131-2143.
142. Mention J.J., Ben Ahmed M., Begue B., et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003, 125:730-745.
143. Backes C., Keller A., Kuentzer J., et al. GeneTrail-advanced gene set enrichment analysis. Nucleic Acid Research, Web Server Issue 2007.